VidaMed wins TUNA (transurethral needle ablation) court battle with ProSurg:
This article was originally published in Clinica
Executive Summary
A US District Court has granted VidaMed's motion for summary judgment against ProSurg for "asking, encouraging or otherwise soliciting physicians to use ProSurg's Opal and Opal Flex products to treat BPH (benign prostatic hyperplasia)." The court found that VidaMed's patent 5,536,240 covering the use of radiofrequency electrodes for treatment of BPH, known as transurethral needle ablation (TUNA), was infringed. VidaMed of Freemont, California, says the decision strengthens its case in ongoing litigation between the two companies.
You may also be interested in...
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: